Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2012 1
2013 3
2014 4
2015 2
2016 3
2017 2
2018 1
2019 3
2020 8
2021 7
2022 6
2023 8
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Chronische Nierenerkrankung bei Psoriasis: eine Kohortenstudie.
Conti A, Giovannini L, Mandel VD, Odorici G, Lasagni C, Bigi L, Pellacani G, Cappelli G. Conti A, et al. Among authors: lasagni c. J Dtsch Dermatol Ges. 2020 May;18(5):438-446. doi: 10.1111/ddg.14087_g. J Dtsch Dermatol Ges. 2020. PMID: 32413229 German.
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: lasagni c. Front Immunol. 2024 Jan 11;14:1341708. doi: 10.3389/fimmu.2023.1341708. eCollection 2023. Front Immunol. 2024. PMID: 38274801 Free PMC article.
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.
Fargnoli MC, Bardazzi F, Bianchi L, Dapavo P, Fabbrocini G, Gisondi P, Micali G, Offidani AM, Pellacani G, Skroza N, Angileri RG, Burlando M, Campanati A, Carrera CG, Chiricozzi A, Conti A, Simone C, Di Lernia V, Errichetti E, Galluzzo M, Guarneri C, Lasagni C, Lembo S, Loconsole F, Megna M, Musumeci ML, Prignano F, Richetta AG, Trovato E, Venturini M, Peris K, Pinton PC. Fargnoli MC, et al. Among authors: lasagni c. J Clin Med. 2023 May 18;12(10):3545. doi: 10.3390/jcm12103545. J Clin Med. 2023. PMID: 37240650 Free PMC article.
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: lasagni c. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e113-e116. doi: 10.1111/jdv.19464. Epub 2023 Aug 29. J Eur Acad Dermatol Venereol. 2024. PMID: 37611277 No abstract available.
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Sampogna F, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: lasagni c. Front Med (Lausanne). 2023 Jul 3;10:1196966. doi: 10.3389/fmed.2023.1196966. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37469659 Free PMC article.
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: lasagni c. J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495. J Clin Med. 2024. PMID: 38256629 Free PMC article.
Chronic kidney disease in psoriasis: a cohort study.
Conti A, Giovannini L, Mandel VD, Odorici G, Lasagni C, Bigi L, Pellacani G, Cappelli G. Conti A, et al. Among authors: lasagni c. J Dtsch Dermatol Ges. 2020 May;18(5):438-445. doi: 10.1111/ddg.14087. Epub 2020 Apr 20. J Dtsch Dermatol Ges. 2020. PMID: 32311824
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Orsini D, Malagoli P, Balato A, Bianchi L, Brianti P, Buononato D, Burlando M, Caldarola G, Campanati A, Campione E, Carrera CG, Carugno A, Cusano F, Dapavo P, Dattola A, De Simone C, Dini V, Esposito M, Fargnoli MC, Gaiani FM, Gargiulo L, Gisondi P, Giunta A, Ibba L, Lasagni C, Loconsole F, Maione V, Mortato E, Marzano AV, Maurelli M, Megna M, Mercuri SR, Narcisi A, Offidani A, Paolino G, Parodi A, Pellacani G, Potestio L, Quaglino P, Richetta AG, Romano F, Sena P, Venturini M, Assorgi C, Costanzo A. Orsini D, et al. Among authors: lasagni c. Dermatol Pract Concept. 2024 Apr 1. doi: 10.5826/dpc.1402a52. Online ahead of print. Dermatol Pract Concept. 2024. PMID: 38416060 Free article.
46 results